Valerio Therapeutics Société anonyme Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Shefali Agarwal

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.2yrs
Promedio de permanencia en la Junta Directiva	3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Shefali Agarwal (50 yo)

2.8yrs

Permanencia

Dr. Agarwal is President, CEO & Chairwoman of Valerio Therapeutics Société anonyme from April 07, 2022. Dr. Agarwal was Independent Director & President of Valerio Therapeutics Société anonyme from July 29...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Shefali Agarwal	President	2.8yrs	sin datos	sin datos
Joyce Carey	Executive Director of Finance and Head of FP&A	1.2yrs	sin datos	sin datos
Robin Sutherland	VP & Global Head of Human Resources	1.3yrs	sin datos	sin datos
Michel Forest	Chief Pharmacist & Quality Assurance Director	no data	sin datos	sin datos
Huiping Jiang	Senior Vice President of Regulatory Affairs & Quality Assurance	1.7yrs	sin datos	sin datos
Wael Jdey	Head of Preclinical	1.2yrs	sin datos	sin datos
Donna Cabral-Lilly	VP & Head of CMC	1.2yrs	sin datos	sin datos
Pam Slatcher	Head of Global PV	less than a year	sin datos	sin datos

1.2yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de C4X no se considera experimentado ( 1.1 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Shefali Agarwal	President	2.9yrs	sin datos	sin datos
Jacques Mallet	Independent Director	2.6yrs	sin datos	sin datos
Khalil Barrage	Representative Director	1.9yrs	sin datos	sin datos
Julien Miara	Director	3.7yrs	sin datos	sin datos
Nicolas Trebouta	Representative Director	12.9yrs	sin datos	sin datos
Ruth Plummer	Member of Scientific Advisory Committee	3yrs	sin datos	sin datos
Bryan Giraudo	Independent Director	2.5yrs	sin datos	sin datos
Robert Coleman	Independent Director	2.6yrs	sin datos	sin datos
Gilbert Chu	Member of Scientific Advisory Committee	3yrs	sin datos	sin datos
Gilles Favre	Member of Scientific Advisory Committee	3yrs	sin datos	sin datos
Lorenzo Galluzzi	Member of Scientific Advisory Committee	3yrs	sin datos	sin datos
Caroline Robert	Member of Scientific Advisory Committee	3yrs	sin datos	sin datos

3.0yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de C4X se considera experimentada (3 años de antigüedad promedio).

Valerio Therapeutics Société anonyme Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Onxeo S.A. Appoints Khalil Barrage as New Board Member

Onxeo SA, Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Onxeo S.A. Announces Executive Changes

Onxeo SA Announces Board Changes

Recent updates

Onxeo SA to Report Fiscal Year 2022 Results on Mar 30, 2023

Onxeo SA Provides Update on the Development Program For Drug Candidate AsiDNATM

Onxeo SA Advances Its Second Lead Candidate Ox425 for the Treatment of Solid Tumors

Onxeo SA Announces the Enrollment of the First Patient in the Phase 1B/2 Clinical Study Conducted by the European Itcc Consortium and Sponsored by Institut Curie

Nasdaq Approves the Delisting of Onxeo's Shares from the First North Growth Market in Copenhagen

Onxeo Ordinary Shares to Be Deleted from OTC Equity

Onxeo SA Announces U.S. Food and Drug Administration Clears Initial IND Drug Candidate AsiDNA

Onxeo S.A. Appoints Khalil Barrage as New Board Member

Onxeo SA, Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Full year 2021 earnings released: €0.07 loss per share (vs €0.015 profit in FY 2020)

Onxeo S.A. Announces Executive Changes

Onxeo SA to Present New Preclinical Data Highlighting Asidna’s Ability to Fight Tumor Resistance and Protect from Anticancer Treatment Toxicity At Aacr Annual Meeting 2022

Onxeo SA to Present New Preclinical Data Highlighting Asidna’s Ability to Fight Tumor Resistance and Protect from Anticancer Treatment Toxicity At Aacr Annual Meeting 2022

Onxeo’s New Preclinical Data Confirm the Relevance of Combining AsiDNA™ With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors

First half 2021 earnings released: €0.057 loss per share (vs €0.075 profit in 1H 2020)

Onxeo S.A. Receives Notice of Allowance for New Patent Broadening the Protection of AsiDNA™ in Combination with a PARP Inhibitor in the United States

Full year 2020 earnings released: EPS €0.01 (vs €0.55 loss in FY 2019)

Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a Phase 1b/2 Clinical Trial of AsiDN

Onxeo SA to Report First Half, 2021 Results on Jul 28, 2021

New 90-day high: €0.73

Onxeo S.A. Announces Completion of Patient Enrollment in DRIIV-1b Study

New 90-day low: €0.60

First half earnings released

New 90-day low: €0.65

First half earnings released

Onxeo SA Announces Board Changes

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad